Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 62

1.

Immunogenicity of HIV virus-like particles in rhesus macaques by intranasal administration.

Buonaguro L, Tagliamonte M, Visciano ML, Andersen H, Lewis M, Pal R, Tornesello ML, Schroeder U, Hinkula J, Wahren B, Buonaguro FM.

Clin Vaccine Immunol. 2012 Jun;19(6):970-3. doi: 10.1128/CVI.00068-12. Epub 2012 Mar 29.

2.

Mucosal and systemic anti-HIV responses in rhesus macaques following combinations of intranasal and parenteral immunizations.

Vajdy M, Singh M, Kazzaz J, Soenawan E, Ugozzoli M, Zhou F, Srivastava I, Bin Q, Barnett S, Donnelly J, Luciw P, Adamson L, Montefiori D, O'Hagan DT.

AIDS Res Hum Retroviruses. 2004 Nov;20(11):1269-81.

PMID:
15588349
3.

DNA-VLP prime-boost intra-nasal immunization induces cellular and humoral anti-HIV-1 systemic and mucosal immunity with cross-clade neutralizing activity.

Buonaguro L, Devito C, Tornesello ML, Schröder U, Wahren B, Hinkula J, Buonaguro FM.

Vaccine. 2007 Aug 10;25(32):5968-77. Epub 2007 Jun 11.

PMID:
17629365
4.
5.

Induction of mucosal and systemic antibody responses against the HIV coreceptor CCR5 upon intramuscular immunization and aerosol delivery of a virus-like particle based vaccine.

Hunter Z, Smyth HD, Durfee P, Chackerian B.

Vaccine. 2009 Dec 11;28(2):403-14. doi: 10.1016/j.vaccine.2009.10.035. Epub 2009 Oct 20.

6.

Protection of macaques against vaginal SHIV challenge by systemic or mucosal and systemic vaccinations with HIV-envelope.

Barnett SW, Srivastava IK, Kan E, Zhou F, Goodsell A, Cristillo AD, Ferrai MG, Weiss DE, Letvin NL, Montefiori D, Pal R, Vajdy M.

AIDS. 2008 Jan 30;22(3):339-48. doi: 10.1097/QAD.0b013e3282f3ca57.

PMID:
18195560
7.

Induction of HIV-specific antibody response and protection against vaginal SHIV transmission by intranasal immunization with inactivated SHIV-capturing nanospheres in macaques.

Miyake A, Akagi T, Enose Y, Ueno M, Kawamura M, Horiuchi R, Hiraishi K, Adachi M, Serizawa T, Narayan O, Akashi M, Baba M, Hayami M.

J Med Virol. 2004 Jul;73(3):368-77.

PMID:
15170630
8.

Comparison of intranasal and intramuscular immunization against human immunodeficiency virus type 1 with a DNA-monophosphoryl lipid A adjuvant vaccine.

Sasaki S, Hamajima K, Fukushima J, Ihata A, Ishii N, Gorai I, Hirahara F, Mohri H, Okuda K.

Infect Immun. 1998 Feb;66(2):823-6.

9.

Comparison of intranasal with targeted lymph node immunization using PR8-Flu ISCOM adjuvanted HIV antigens in macaques.

Koopman G, Bogers WM, van Gils M, Koornstra W, Barnett S, Morein B, Lehner T, Heeney JL.

J Med Virol. 2007 May;79(5):474-82.

PMID:
17385685
10.

Mucosally-administered human-simian immunodeficiency virus DNA and fowlpoxvirus-based recombinant vaccines reduce acute phase viral replication in macaques following vaginal challenge with CCR5-tropic SHIVSF162P3.

Kent SJ, Dale CJ, Ranasinghe C, Stratov I, De Rose R, Chea S, Montefiori DC, Thomson S, Ramshaw IA, Coupar BE, Boyle DB, Law M, Wilson KM, Ramsay AJ.

Vaccine. 2005 Oct 10;23(42):5009-21.

PMID:
15985317
11.

Intranasal immunization of young mice with a multigene HIV-1 vaccine in combination with the N3 adjuvant induces mucosal and systemic immune responses.

Bråve A, Hallengärd D, Schröder U, Blomberg P, Wahren B, Hinkula J.

Vaccine. 2008 Sep 19;26(40):5075-8. doi: 10.1016/j.vaccine.2008.03.066. Epub 2008 Apr 15.

PMID:
18450334
13.

DNA vaccine protection against challenge with simian/human immunodeficiency virus 89.6 in rhesus macaques.

Habel A, Chanel C, Le Grand R, Martinon F, Couillin L, Moog C, Doms R, Gauduin MC, Hurtrel B, Guillet JG, Aubertin AM, Girard M.

Dev Biol (Basel). 2000;104:101-5.

PMID:
11713807
14.

Preclinical evaluation of cellular immune responses elicited by a polyvalent DNA prime/protein boost HIV-1 vaccine.

Cristillo AD, Wang S, Caskey MS, Unangst T, Hocker L, He L, Hudacik L, Whitney S, Keen T, Chou TH, Shen S, Joshi S, Kalyanaraman VS, Nair B, Markham P, Lu S, Pal R.

Virology. 2006 Mar 1;346(1):151-68. Epub 2005 Dec 2.

15.

Improved HIV-1 specific T-cell responses by short-interval DNA tattooing as compared to intramuscular immunization in non-human primates.

Verstrepen BE, Bins AD, Rollier CS, Mooij P, Koopman G, Sheppard NC, Sattentau Q, Wagner R, Wolf H, Schumacher TN, Heeney JL, Haanen JB.

Vaccine. 2008 Jun 19;26(26):3346-51. doi: 10.1016/j.vaccine.2008.03.091. Epub 2008 Apr 21.

PMID:
18467010
16.

Immunization of rhesus macaques with a polyvalent DNA prime/protein boost human immunodeficiency virus type 1 vaccine elicits protective antibody response against simian human immunodeficiency virus of R5 phenotype.

Pal R, Kalyanaraman VS, Nair BC, Whitney S, Keen T, Hocker L, Hudacik L, Rose N, Mboudjeka I, Shen S, Wu-Chou TH, Montefiori D, Mascola J, Markham P, Lu S.

Virology. 2006 May 10;348(2):341-53.

17.

Long lived multi-isotype anti-HIV antibody responses following a prime-double boost immunization strategy.

Stambas J, Brown SA, Gutierrez A, Sealy R, Yue W, Jones B, Lockey TD, Zirkel A, Freiden P, Brown B, Surman S, Coleclough C, Slobod KS, Doherty PC, Hurwitz JL.

Vaccine. 2005 Mar 31;23(19):2454-64.

PMID:
15752831
18.

Vaccination of rhesus macaques with recombinant Mycobacterium bovis bacillus Calmette-Guérin Env V3 elicits neutralizing antibody-mediated protection against simian-human immunodeficiency virus with a homologous but not a heterologous V3 motif.

Someya K, Cecilia D, Ami Y, Nakasone T, Matsuo K, Burda S, Yamamoto H, Yoshino N, Kaizu M, Ando S, Okuda K, Zolla-Pazner S, Yamazaki S, Yamamoto N, Honda M.

J Virol. 2005 Feb;79(3):1452-62.

19.

Enhancement of HIV-1 DNA vaccine immunogenicity by BCG-PSN, a novel adjuvant.

Sun J, Hou J, Li D, Liu Y, Hu N, Hao Y, Fu J, Hu Y, Shao Y.

Vaccine. 2013 Jan 7;31(3):472-9. doi: 10.1016/j.vaccine.2012.11.024. Epub 2012 Nov 19.

PMID:
23174201
20.

Supplemental Content

Support Center